The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...

Johnson amp Johnson exceeded Wall Street expectations for fourth-quarter revenue and profit with robust sales of cancer ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Stelara has been a key contributor to the ... JNJ-2113, being developed for multiple indications including ulcerative colitis and psoriasis, is estimated to have peak year sales potential of ...

Will the Stelara biosimilars be a reprise of the Humira biosimilars in 2023 and be slow to catch on? Biosimilar watchers circled 2023 as a red-letter year because that was the year that the Humira ...

The biosimilar, referencing Johnson & Johnson’s (NYSE: JNJ) Stelara, targets inflammatory conditions such as Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The ...

Vigorous protection of Stelara’s position aligns with a strategy to grow in the immunology space. Credit: josefkubes via Shutterstock. During its presentation at the JP Morgan Healthcare Conference ...